Please ensure Javascript is enabled for purposes of website accessibility

Why Dow, Alcoa, and Freeport-McMoRan Stocks Are All Hopping Today

By Rich Smith – May 18, 2020 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New vaccine spurs hopes that the economy could turn around post-coronavirus.

What happened

By now you've probably heard the news: biotech Moderna Inc. appears to have a viable coronavirus vaccine -- "mRNA-1273" -- that "interim Phase 1 data" from a study of 45 people shows to be "generally safe and well tolerated." In at least eight of those subjects, it generated enough of the right kind of antibodies to suggest that it might provide "full protection against viral replication" of the SARS-CoV-19 coronavirus.  

Investors are elated, and the S&P 500 Index of companies is up well over 3% this afternoon on the news. The optimism has spilled over from the biotech sector, too, to infect (in a good way) stocks as far away as the basic materials sectors of chemicals (Dow Chemical (DOW) up 9.4% in 1:45 p.m. EDT trading), copper (Freeport-McMoRan (FCX 1.40%) up 8.4%), and aluminum, too, with Alcoa (AA) shares up an astounding 16.3%!

Three colorful arrows racing straight up on a black background

Image source: Getty Images.

So what

But is this news as good as it seems? After all, it was only four days ago that Alcoa CEO Roy Harvey told Bloomberg that Alcoa lacks "the clarity [or] the orders on the books, to signal that there is a definitive recovery coming." In the meantime, Harvey worries that the global aluminum industry is "producing more aluminum than it needs," which is a recipe for price weakness, and low profits (or losses).  

At Freeport-McMoRan, too, the news isn't great. A rise in coronavirus infections at the company's Grasberg mine in Indonesia is causing Freeport to cut its workforce to a "skeletal team," reports Reuters today, and the company has suspended production at a New Mexico copper mine for similar reasons.  

At Dow, meanwhile ... there are no reports of factory closures today, at least. But what news there is at the company -- an effort to collaborate with other companies such as 3M and DuPont to produce 100,000 "level 2 medical isolation gowns" -- was undercut by Dow's confirmation that the gowns in question will be "donated to healthcare professionals."

While that's great news for frontline healthcare workers, and good news for Americans in general as it shows industry is still stepping up to help fight the virus, there's not a lot of profit margin in producing goods at Dow's own cost, and then giving them away.

Now what

And that is not great news for the investors rushing to buy back into Dow, Freeport, and Alcoa stocks today. Recall that over the past 12 months, all three of these stocks have reported negative earnings. Worse than that, COVID-19 wasn't solely responsible for those losses. According to data from S&P Global Market Intelligence, each of Dow, Freeport, and Alcoa stocks lost money last year as well, before most of us even had any idea what a "coronavirus" was.

Before betting that the end of the pandemic-fueled recession will revive shares of these companies, investors should consider that they were already looking pretty sickly before coronavirus even came on the scene.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alcoa Inc. Stock Quote
Alcoa Inc.
Freeport-McMoRan Inc. Stock Quote
Freeport-McMoRan Inc.
$26.87 (1.40%) $0.37
DuPont de Nemours, Inc. Stock Quote
DuPont de Nemours, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.